What is Sensei Biotherapeutics' operating income?

Sensei Biotherapeutics' total operating income in 2025 was -$22.29 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $22.29 million

Sensei Biotherapeutics (FTH) Financials

$25.94 -5.53 (-17.57%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$26.31 +0.37 (+1.42%)

As of 07/16/2026 08:00 PM Eastern

Compare

Annual Income Statements for Sensei Biotherapeutics

This table shows Sensei Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-20	-37	-49	-34	-30	-21
Consolidated Net Income / (Loss)	-20	-37	-49	-34	-30	-21
Net Income / (Loss) Continuing Operations	-20	-37	-49	-34	-30	-21
Total Pre-Tax Income	-20	-37	-49	-34	-30	-21
Total Operating Income	-19	-37	-50	-37	-33	-22
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	19	37	50	37	33	22
Selling, General & Admin Expense	7.53	16	20	19	13	11
Research & Development Expense	11	22	30	18	19	11
Impairment Charge	-	-	-	0.00	0.95	0.00
Total Other Income / (Expense), net	-0.69	0.12	1.56	3.48	2.46	1.21
Interest Expense	1.69	0.67	0.22	0.14	0.09	0.03
Interest & Investment Income	0.00	0.80	1.78	3.62	2.55	1.24
Other Income / (Expense), net	1.00	-0.01	0.00	0.00	-0.00	0.00
Other Gains / (Losses), net	0.05	0.57	0.04	-0.22	-	-0.00
Basic Earnings per Share	($12.53)	($1.33)	($1.58)	($1.22)	($24.01)	($16.72)
Weighted Average Basic Shares Outstanding	1.61M	27.71M	30.70M	27.95M	1.26M	1.26M
Diluted Earnings per Share	($12.53)	($1.33)	($1.58)	($1.22)	($24.01)	($16.72)
Weighted Average Diluted Shares Outstanding	1.61M	27.71M	30.70M	27.95M	1.26M	1.26M
Weighted Average Basic & Diluted Shares Outstanding	1.61M	27.71M	30.97M	25.07M	25.21M	1.34M

This table shows Sensei Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-7.12	-7.52	-7.99	-7.14	-7.25	-7.77	-6.86	-4.94	-4.57	-4.72	-170
Consolidated Net Income / (Loss)	-7.12	-7.41	-7.99	-7.14	-7.25	-7.77	-6.86	-4.94	-4.57	-4.72	-170
Net Income / (Loss) Continuing Operations	-7.12	-7.22	-7.99	-7.14	-7.25	-7.77	-6.86	-4.90	-4.57	-4.74	-170
Total Pre-Tax Income	-7.12	-7.01	-7.99	-7.14	-7.25	-7.77	-6.86	-4.90	-4.57	-4.73	-170
Total Operating Income	-7.74	-8.14	-8.73	-7.79	-7.82	-8.27	-7.27	-5.21	-4.85	-4.96	-171
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	7.74	8.14	8.73	7.79	7.82	8.27	7.27	5.25	4.85	4.94	171
Selling, General & Admin Expense	3.92	3.65	3.81	3.20	3.19	2.83	3.55	2.67	2.32	2.79	20
Research & Development Expense	3.82	4.49	4.92	4.58	4.64	4.49	3.73	2.53	2.54	2.17	151
Total Other Income / (Expense), net	0.62	0.94	0.74	0.65	0.57	0.50	0.41	0.31	0.28	0.22	0.39
Interest & Investment Income	0.88	0.83	0.77	0.67	0.59	0.52	0.39	0.32	0.29	0.22	0.39
Other Income / (Expense), net	-0.23	0.15	-0.00	0.00	0.00	-0.00	0.02	-0.00	0.00	0.00	-0.00
Basic Earnings per Share	($0.28)	($0.30)	($0.32)	($5.69)	($5.77)	($6.19)	($5.45)	($3.91)	($3.62)	($3.74)	($131.45)
Weighted Average Basic Shares Outstanding	25.51M	27.95M	25.05M	1.26M	1.26M	1.26M	1.26M	1.26M	1.26M	1.26M	1.30M
Diluted Earnings per Share	($0.28)	($0.30)	($0.32)	($5.69)	($5.77)	($6.19)	($5.45)	($3.91)	($3.62)	($3.74)	($131.45)
Weighted Average Diluted Shares Outstanding	25.51M	27.95M	25.05M	1.26M	1.26M	1.26M	1.26M	1.26M	1.26M	1.26M	1.30M
Weighted Average Basic & Diluted Shares Outstanding	25.00M	25.07M	25.08M	25.15M	25.15M	25.21M	25.21M	1.26M	1.26M	1.34M	1.34M

This table details how cash moves in and out of Sensei Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	16	-9.44	11	-4.78	-3.02	-1.33
Net Cash From Operating Activities	-18	-30	-39	-32	-25	-20
Net Cash From Continuing Operating Activities	-18	-30	-39	-32	-25	-20
Net Income / (Loss) Continuing Operations	-20	-37	-49	-34	-30	-21
Consolidated Net Income / (Loss)	-20	-37	-49	-34	-30	-21
Depreciation Expense	0.21	0.69	0.61	0.57	0.55	0.12
Amortization Expense	-	0.00	0.73	0.78	0.77	0.02
Non-Cash Adjustments To Reconcile Net Income	2.64	5.68	7.21	5.06	4.65	2.09
Changes in Operating Assets and Liabilities, net	-0.45	0.12	1.01	-4.33	-0.49	-1.59
Net Cash From Investing Activities	-1.40	-143	50	38	22	20
Net Cash From Continuing Investing Activities	-1.40	-143	50	38	22	20
Purchase of Property, Plant & Equipment	-1.21	-2.03	-0.32	-0.18	-0.15	-0.02
Purchase of Investments	0.00	-184	-47	-21	-45	-25
Sale of Property, Plant & Equipment	0.00	0.32	0.02	0.17	0.00	0.25
Sale and/or Maturity of Investments	0.00	42	97	60	67	45
Net Cash From Financing Activities	35	164	-0.29	-11	-0.79	-0.65
Net Cash From Continuing Financing Activities	35	164	-0.29	-11	-0.79	-0.65
Repurchase of Common Equity	-	-	0.00	-10	0.00	0.00
Other Financing Activities, net	0.55	0.11	-0.29	-0.79	-0.79	-0.65

This table details how cash moves in and out of Sensei Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	1.12	1.67	-2.06	0.94	7.24	-9.14	-0.12	2.68	-2.00	-1.89	144
Net Cash From Operating Activities	-4.66	-6.16	-7.62	-5.79	-5.47	-5.79	-7.09	-5.91	-3.59	-3.86	-11
Net Cash From Continuing Operating Activities	-4.66	-6.16	-7.62	-5.79	-5.47	-5.79	-7.09	-5.91	-3.59	-3.86	-11
Net Income / (Loss) Continuing Operations	-7.12	-7.41	-7.99	-7.14	-7.25	-7.77	-6.86	-4.94	-4.57	-4.72	-170
Consolidated Net Income / (Loss)	-7.12	-7.41	-7.99	-7.14	-7.25	-7.77	-6.86	-4.94	-4.57	-4.72	-170
Depreciation Expense	0.14	0.14	0.14	0.14	0.14	0.14	0.03	0.03	0.03	0.03	0.03
Amortization Expense	0.20	0.19	0.19	0.19	0.19	0.19	0.00	0.01	0.00	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	1.15	1.32	1.47	0.94	0.85	1.40	0.60	0.48	0.48	0.53	146
Changes in Operating Assets and Liabilities, net	0.98	-0.40	-1.43	0.09	0.60	0.25	-0.86	-1.49	0.47	0.29	13
Net Cash From Investing Activities	8.31	8.26	5.77	6.91	13	-3.15	7.19	8.76	1.74	2.08	-31
Net Cash From Continuing Investing Activities	8.31	8.26	5.77	6.91	13	-3.15	7.19	8.76	1.74	2.08	-31
Purchase of Property, Plant & Equipment	-	-	-0.04	-0.11	-	-	0.00	-0.02	-	-	-0.01
Acquisitions	-	-	-	-	-	-	0.00	-	-	-	6.46
Purchase of Investments	-8.69	-2.61	-6.26	-12	-8.84	-18	-6.35	-2.44	-9.85	-6.52	-44
Sale of Property, Plant & Equipment	-	-	0.00	-	-	-	0.04	0.21	-	-	0.00
Sale and/or Maturity of Investments	17	11	12	19	22	15	14	11	12	8.60	6.00
Net Cash From Financing Activities	-2.53	-0.43	-0.21	-0.18	-0.20	-0.19	-0.21	-0.17	-0.15	-0.11	186
Net Cash From Continuing Financing Activities	-2.53	-0.43	-0.21	-0.18	-0.20	-0.19	-0.21	-0.17	-0.15	-0.11	186
Repurchase of Common Equity	-2.34	-0.25	0.00	-	-	-	0.00	-	-	-	0.00
Issuance of Preferred Equity	-	-	-	-	-	-	0.00	-	-	-	200
Issuance of Common Equity	-	-	-	-	-	-	0.00	-	-	-	-15
Other Financing Activities, net	-0.19	-0.18	-0.21	-0.18	-0.20	-0.19	-0.21	-0.17	-0.15	-0.11	0.97

This table presents Sensei Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	21	153	118	74	45	23
Total Current Assets	20	149	109	67	42	22
Cash & Equivalents	17	7.16	18	13	9.99	8.67
Short-Term Investments	0.00	140	89	53	31	13
Accounts Receivable	-	-	-	-	-	0.00
Prepaid Expenses	1.38	0.55	1.13	1.17	0.47	0.23
Other Current Assets	2.11	0.37	0.34	0.33	0.12	0.09
Plant, Property, & Equipment, net	1.27	4.64	2.05	1.17	0.42	0.08
Total Noncurrent Assets	0.09	0.04	7.74	5.96	3.02	1.31
Noncurrent Note & Lease Receivables	-	0.00	2.32	1.54	0.16	0.00
Other Noncurrent Operating Assets	0.09	0.04	5.42	4.42	2.85	1.31
Total Liabilities & Shareholders' Equity	21	153	118	74	45	23
Total Liabilities	5.54	6.71	15	9.48	6.98	4.31
Total Current Liabilities	4.83	4.89	9.07	5.64	5.45	4.25
Accounts Payable	3.88	2.46	4.47	1.69	1.25	1.48
Current Employee Benefit Liabilities	0.92	1.75	2.46	1.51	1.88	1.32
Other Current Liabilities	0.03	0.68	2.13	2.44	2.32	1.45
Total Noncurrent Liabilities	0.71	1.82	5.90	3.84	1.53	0.06
Other Noncurrent Operating Liabilities	0.05	1.82	4.32	3.07	1.43	0.06
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	72	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-56	147	103	65	38	19
Total Preferred & Common Equity	-56	147	103	65	38	19
Preferred Stock	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-56	147	103	65	38	19
Common Stock	56	296	302	297	300	302
Retained Earnings	-112	-149	-198	-232	-262	-283
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.33	-1.00	-0.21	-0.01	0.00

This table presents Sensei Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	82	67	60	53	38	32	28	205
Total Current Assets	74	60	54	48	36	30	26	204
Cash & Equivalents	11	11	12	19	9.88	13	11	152
Short-Term Investments	61	47	40	28	24	16	14	50
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Prepaid Expenses	1.51	1.88	1.51	1.02	0.91	0.83	0.50	0.97
Other Current Assets	0.32	0.27	0.14	0.08	0.44	0.12	0.25	0.47
Plant, Property, & Equipment, net	1.30	1.07	1.04	0.90	0.16	0.14	0.11	0.07
Total Noncurrent Assets	6.52	5.40	4.82	4.26	2.43	2.07	1.69	1.08
Noncurrent Note & Lease Receivables	1.74	1.35	1.16	0.96	0.02	0.01	0.01	0.00
Other Noncurrent Operating Assets	4.79	4.05	3.66	3.29	2.42	2.06	1.69	1.08
Total Liabilities & Shareholders' Equity	82	67	60	53	38	32	28	205
Total Liabilities	11	8.22	7.61	7.48	6.29	4.47	4.58	14
Total Current Liabilities	6.23	4.99	4.95	5.44	5.23	3.87	4.44	14
Accounts Payable	2.73	2.00	1.65	1.68	2.36	1.14	1.41	8.98
Current Employee Benefit Liabilities	1.09	0.51	0.85	1.33	0.72	0.78	1.16	4.17
Other Current Liabilities	2.41	2.48	2.46	2.43	2.15	1.96	1.88	1.04
Total Noncurrent Liabilities	4.43	3.23	2.66	2.03	1.06	0.60	0.15	0.00
Other Noncurrent Operating Liabilities	3.47	2.66	2.28	1.83	1.02	0.59	0.15	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	328
Total Equity & Noncontrolling Interests	71	58	52	46	32	27	23	-137
Total Preferred & Common Equity	71	58	52	46	32	27	23	-137
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	71	58	52	46	32	27	23	-137
Common Stock	296	298	299	300	301	301	301	316
Retained Earnings	-224	-240	-247	-254	-269	-274	-278	-453
Accumulated Other Comprehensive Income / (Loss)	-0.40	-0.14	-0.09	0.01	-0.01	-0.01	-0.00	-0.02

This table displays calculated financial ratios and metrics derived from Sensei Biotherapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	30,596,828.00	30,720,291.00	24,996,517.00	25,151,379.00	1,261,290.00
DEI Adjusted Shares Outstanding	0.00	1,529,841.00	1,536,015.00	1,249,826.00	1,257,569.00	1,261,290.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-24.05	-31.63	-27.28	-23.98	-16.72
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-101.71%	-32.70%	26.88%	12.37%	29.23%
EBIT Growth	0.00%	-103.14%	-33.87%	26.15%	12.00%	31.67%
NOPAT Growth	0.00%	-92.70%	-33.90%	26.15%	12.01%	31.66%
Net Income Growth	0.00%	-83.05%	-32.05%	29.82%	11.57%	30.08%
EPS Growth	0.00%	89.39%	-18.80%	22.78%	11.57%	30.36%
Operating Cash Flow Growth	0.00%	-70.91%	-28.97%	17.94%	22.96%	17.09%
Free Cash Flow Firm Growth	0.00%	0.00%	-35.47%	17.97%	28.26%	20.98%
Invested Capital Growth	0.00%	-2,116.00%	-92.24%	95.59%	-2,932.98%	9.08%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	-12.49%	-7.99%	12.43%	-0.90%	12.00%
EBIT Q/Q Growth	0.00%	-13.11%	-7.81%	12.07%	-0.87%	12.96%
NOPAT Q/Q Growth	0.00%	-13.08%	-7.81%	11.69%	-0.41%	12.95%
Net Income Q/Q Growth	0.00%	-13.01%	-6.27%	12.38%	-1.19%	12.65%
EPS Q/Q Growth	0.00%	62.75%	-8.97%	7.58%	-1.19%	12.64%
Operating Cash Flow Q/Q Growth	0.00%	-20.69%	-4.57%	9.63%	1.48%	8.61%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-2.89%	7.40%	7.81%	6.18%
Invested Capital Q/Q Growth	0.00%	23.80%	-139.33%	-84.31%	-180.61%	-27.43%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	99.78%	98.48%	99.93%	101.54%	100.00%	100.02%
Interest Burden Percent	109.15%	99.65%	96.88%	90.61%	92.46%	94.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-126.47%	-45.31%	-38.88%	-40.52%	-58.40%	-74.01%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	449.15%	-25.13%	-38.88%	-40.52%	-58.40%	-74.01%
Return on Equity Simple (ROE_SIMPLE)	35.61%	-25.11%	-46.99%	-52.55%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	-26	-35	-26	-23	-16
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-40.67%	-12.91%	-10.63%	-9.57%	-13.80%	-17.57%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-39.51%	-59.32%	-83.92%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-18	-37	-50	-37	-33	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	-37	-49	-36	-31	-22
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.21	0.44	0.27	0.32	0.72
Price to Tangible Book Value (P/TBV)	0.00	1.21	0.44	0.27	0.32	0.72
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.04	0.00	0.02	0.01	0.00	0.00
Long-Term Debt to Equity	0.04	0.00	0.02	0.01	0.00	0.00
Financial Leverage	-1.00	-1.01	-1.01	-1.01	-1.03	-1.10
Leverage Ratio	1.35	1.08	1.09	1.15	1.16	1.20
Compound Leverage Factor	1.47	1.07	1.05	1.04	1.07	1.13
Debt to Total Capital	3.95%	0.00%	1.50%	1.17%	0.25%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	3.95%	0.00%	1.50%	1.17%	0.25%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	437.18%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-341.13%	100.00%	98.50%	98.83%	99.75%	100.00%
Debt to EBITDA	-0.04	0.00	-0.03	-0.02	0.00	0.00
Net Debt to EBITDA	0.87	0.00	2.16	1.82	1.32	0.00
Long-Term Debt to EBITDA	-0.04	0.00	-0.03	-0.02	0.00	0.00
Debt to NOPAT	-0.05	0.00	-0.04	-0.03	0.00	0.00
Net Debt to NOPAT	1.17	0.00	3.00	2.50	1.81	0.00
Long-Term Debt to NOPAT	-0.05	0.00	-0.04	-0.03	0.00	0.00
Altman Z-Score	5.08	14.82	-0.89	-3.92	-8.44	-17.74
Noncontrolling Interest Sharing Ratio	455.14%	44.54%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	4.16	30.38	11.98	11.92	7.70	5.06
Quick Ratio	3.44	30.19	11.82	11.65	7.59	4.98
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-25	-34	-28	-20	-16
Operating Cash Flow to CapEx	-1,468.08%	-1,771.60%	-12,753.59%	-228,735.71%	-16,897.26%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-37.58	-155.75	-194.31	-223.03	-495.64
Operating Cash Flow to Interest Expense	-10.48	-45.16	-178.20	-222.38	-274.11	-639.16
Operating Cash Flow Less CapEx to Interest Expense	-11.20	-47.71	-179.60	-222.48	-275.73	-631.84
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-0.05	-1.11	-2.13	-0.09	-2.85	-2.59
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-1.06	-1.02	2.04	-2.76	0.26
Enterprise Value (EV)	189	30	-60	-48	-29	-7.73
Market Capitalization	133	177	46	17	12	13
Book Value per Share	($35.01)	$4.79	$3.37	$2.60	$1.53	$14.74
Tangible Book Value per Share	($35.01)	$4.79	$3.37	$2.60	$1.53	$14.74
Total Capital	17	147	105	66	38	19
Total Debt	0.65	0.00	1.58	0.77	0.10	0.00
Total Long-Term Debt	0.65	0.00	1.58	0.77	0.10	0.00
Net Debt	-16	-148	-106	-65	-41	-21
Capital Expenditures (CapEx)	1.21	1.71	0.31	0.01	0.15	-0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.35	-3.97	-7.59	-4.15	-4.85	-3.93
Debt-free Net Working Capital (DFNWC)	15	144	100	62	36	17
Net Working Capital (NWC)	15	144	100	62	36	17
Net Nonoperating Expense (NNE)	6.48	11	13	8.16	7.33	5.48
Net Nonoperating Obligations (NNO)	-16	-148	-106	-65	-41	-21
Total Depreciation and Amortization (D&A)	0.21	0.69	1.35	1.35	1.32	0.14
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.33)	($1.58)	($1.22)	($24.00)	($16.72)
Adjusted Weighted Average Basic Shares Outstanding	0.00	30.68M	30.70M	27.95M	1.26M	1.26M
Adjusted Diluted Earnings per Share	$0.00	($1.33)	($1.58)	($1.22)	($24.00)	($16.72)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	30.68M	30.70M	27.95M	1.26M	1.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.33)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	27.71M	30.97M	25.07M	1.26M	1.34M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-26	-35	-26	-22	-16
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-10.93	-55.96	-229.17	-257.39	-362.41	-696.50
NOPAT to Interest Expense	-8.06	-39.16	-160.42	-180.17	-253.66	-487.55
EBIT Less CapEx to Interest Expense	-11.64	-58.51	-230.57	-257.49	-364.03	-689.19
NOPAT Less CapEx to Interest Expense	-8.78	-41.71	-161.82	-180.27	-255.29	-480.24
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-30.45%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sensei Biotherapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	26,583,819.00	24,996,517.00	25,070,980.00	25,080,958.00	25,151,129.00	25,151,379.00	25,208,068.00	25,208,068.00	1,261,290.00	1,261,290.00	1,340,281.00
DEI Adjusted Shares Outstanding	1,329,191.00	1,249,826.00	1,253,549.00	1,254,048.00	1,257,556.00	1,257,569.00	1,260,403.00	1,260,403.00	1,261,290.00	1,261,290.00	1,340,281.00
DEI Earnings Per Adjusted Shares Outstanding	-5.36	-6.02	-6.38	-5.70	-5.77	-6.18	-5.45	-3.92	-3.62	-3.74	-127.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	43.81%	39.80%	21.05%	23.71%	1.82%	-3.64%	14.03%	30.69%	35.70%	38.07%	-2,262.20%
EBIT Growth	42.81%	38.90%	20.61%	22.97%	1.75%	-3.52%	16.90%	33.13%	37.99%	40.13%	-2,251.54%
NOPAT Growth	44.50%	37.60%	20.69%	23.48%	-1.11%	-1.62%	16.68%	33.15%	37.99%	40.09%	-2,245.71%
Net Income Growth	46.90%	39.39%	21.47%	23.91%	-1.81%	-4.80%	14.11%	30.89%	37.01%	39.31%	-2,380.13%
EPS Growth	36.36%	25.00%	3.03%	23.91%	-1.81%	-4.80%	14.11%	31.28%	37.26%	39.58%	-2,311.93%
Operating Cash Flow Growth	31.49%	35.63%	35.11%	38.79%	-17.36%	6.02%	6.85%	-2.02%	34.44%	33.29%	-51.30%
Free Cash Flow Firm Growth	39.41%	4.64%	14.52%	10.80%	27.88%	60.77%	71.51%	51.23%	47.29%	-22.87%	-5,955.91%
Invested Capital Growth	94.27%	95.59%	39.31%	-81.57%	-1,892.16%	-2,932.98%	-339.52%	-567.86%	-100.20%	9.08%	-402.51%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	21.96%	-0.46%	-9.60%	11.21%	-0.43%	-6.05%	9.09%	28.61%	6.83%	-2.14%	-3,367.44%
EBIT Q/Q Growth	21.24%	-0.40%	-9.23%	10.82%	-0.46%	-5.78%	12.31%	28.44%	6.84%	-2.12%	-3,344.25%
NOPAT Q/Q Growth	23.98%	-5.23%	-7.22%	10.80%	-0.46%	-5.77%	12.09%	28.43%	6.82%	-2.19%	-3,342.14%
Net Income Q/Q Growth	24.10%	-4.07%	-7.80%	10.64%	-1.55%	-7.13%	11.66%	28.09%	7.44%	-3.22%	-3,509.75%
EPS Q/Q Growth	9.68%	-7.14%	-6.67%	10.64%	-1.55%	-7.13%	11.66%	-1,348.15%	7.42%	-3.31%	-3,414.71%
Operating Cash Flow Q/Q Growth	50.75%	-32.22%	-23.58%	23.95%	5.56%	-5.89%	-22.48%	16.70%	39.31%	-7.75%	-177.77%
Free Cash Flow Firm Q/Q Growth	-32.47%	-23.67%	17.48%	34.01%	-7.10%	32.73%	40.07%	-12.94%	-15.75%	-56.83%	-2,853.82%
Invested Capital Q/Q Growth	-103.36%	-84.31%	1,125.53%	-70.95%	-462.86%	-180.61%	19.01%	43.27%	-55.27%	-27.43%	-347.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.08%	105.79%	100.00%	100.00%	100.00%	100.00%	100.00%	100.82%	100.02%	99.64%	100.00%
Interest Burden Percent	89.40%	87.67%	91.53%	91.72%	92.71%	93.90%	94.60%	94.03%	94.17%	95.54%	99.77%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-42.08%	-40.52%	-41.63%	-45.17%	-51.04%	-58.40%	-64.18%	-67.47%	-70.19%	-74.01%	-165.30%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-2,973.70%	-2,383.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-42.08%	-40.52%	-41.63%	-45.17%	-51.04%	-58.40%	-64.18%	-67.47%	-70.19%	-74.01%	77.99%
Return on Equity Simple (ROE_SIMPLE)	-54.82%	0.00%	-54.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.42	-5.70	-6.11	-5.45	-5.48	-5.79	-5.09	-3.64	-3.40	-3.47	-119
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.84%	-2.01%	-2.48%	-2.61%	-3.02%	-3.72%	-3.86%	-3.21%	-3.27%	-3.99%	-42.85%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.68%	-10.35%	-10.37%	-11.91%	-15.05%	-15.90%	-13.34%	-14.76%	-18.66%	87.00%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-7.96	-7.99	-8.73	-7.79	-7.82	-8.28	-7.26	-5.21	-4.85	-4.95	-171
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.63	-7.67	-8.40	-7.46	-7.49	-7.94	-7.22	-5.17	-4.82	-4.92	-171
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.30	0.27	0.45	0.30	0.33	0.32	0.31	0.40	0.52	0.72	0.00
Price to Tangible Book Value (P/TBV)	0.30	0.27	0.45	0.30	0.33	0.32	0.31	0.40	0.52	0.72	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.01	-0.99	-0.99	-1.01	-1.03	-1.01	-1.01	-1.04	-1.10	-1.06
Leverage Ratio	1.14	1.15	1.14	1.14	1.16	1.16	1.16	1.15	1.18	1.20	1.09
Compound Leverage Factor	1.02	1.00	1.04	1.04	1.07	1.09	1.10	1.08	1.11	1.14	1.09
Debt to Total Capital	1.34%	1.17%	0.97%	0.72%	0.45%	0.25%	0.11%	0.01%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	1.34%	1.17%	0.97%	0.72%	0.45%	0.25%	0.11%	0.01%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	171.81%
Common Equity to Total Capital	98.66%	98.83%	99.03%	99.28%	99.55%	99.75%	99.89%	99.99%	100.00%	100.00%	-71.81%
Debt to EBITDA	-0.02	-0.02	-0.02	-0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.74	1.82	1.72	1.67	1.51	1.32	1.14	1.03	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.02	-0.02	-0.02	-0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.03	-0.03	-0.02	-0.02	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.42	2.50	2.36	2.29	2.06	1.81	1.57	1.43	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.03	-0.03	-0.02	-0.02	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.98	-2.63	-2.55	-4.00	-5.00	-6.66	-8.56	-10.18	-12.22	-15.24	-2.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	147.18%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.86	11.92	12.07	10.90	8.84	7.70	6.82	7.64	5.81	5.06	14.39
Quick Ratio	11.57	11.65	11.63	10.57	8.64	7.59	6.57	7.39	5.65	4.98	14.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.25	-7.74	-6.38	-4.21	-4.51	-3.03	-1.82	-2.05	-2.38	-3.73	-110
Operating Cash Flow to CapEx	0.00%	0.00%	-20,583.78%	-5,313.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-178,883.33%
Free Cash Flow to Firm to Interest Expense	-189.54	-249.53	-227.96	-175.50	-214.81	-178.52	0.00	-205.42	-396.28	-1,242.97	0.00
Operating Cash Flow to Interest Expense	-141.24	-198.81	-272.00	-241.33	-260.48	-340.71	0.00	-590.90	-597.67	-1,288.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-141.24	-198.81	-273.32	-245.88	-260.48	-340.71	0.00	-571.50	-597.67	-1,288.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.05	-0.09	0.96	0.28	-1.02	-2.85	-2.31	-1.31	-2.03	-2.59	-12
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.84	2.04	0.27	-1.24	-0.97	-2.76	-3.27	-1.59	-1.02	0.26	-9.29
Enterprise Value (EV)	-50	-48	-31	-36	-32	-29	-24	-18	-13	-7.73	168
Market Capitalization	21	17	26	16	15	12	9.93	11	12	13	42
Book Value per Share	$2.67	$2.60	$2.33	$2.08	$1.82	$1.53	$1.27	$1.08	$18.24	$14.74	($102.43)
Tangible Book Value per Share	$2.67	$2.60	$2.33	$2.08	$1.82	$1.53	$1.27	$1.08	$18.24	$14.74	($102.43)
Total Capital	72	66	59	53	46	38	32	27	23	19	191
Total Debt	0.96	0.77	0.57	0.38	0.21	0.10	0.04	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.96	0.77	0.57	0.38	0.21	0.10	0.04	0.00	0.00	0.00	0.00
Net Debt	-71	-65	-58	-52	-47	-41	-34	-29	-25	-21	-203
Capital Expenditures (CapEx)	0.00	0.00	0.04	0.11	0.00	0.00	-0.04	-0.19	0.00	0.00	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.40	-4.15	-2.84	-3.29	-4.34	-4.85	-3.88	-2.93	-3.69	-3.93	-13
Debt-free Net Working Capital (DFNWC)	68	62	55	49	43	36	30	26	21	17	190
Net Working Capital (NWC)	68	62	55	49	43	36	30	26	21	17	190
Net Nonoperating Expense (NNE)	1.71	1.71	1.88	1.69	1.78	1.98	1.77	1.29	1.17	1.25	51
Net Nonoperating Obligations (NNO)	-71	-65	-58	-52	-47	-41	-34	-29	-25	-21	-203
Total Depreciation and Amortization (D&A)	0.33	0.33	0.33	0.33	0.33	0.33	0.03	0.04	0.03	0.03	0.03
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.30)	($0.32)	($5.60)	($5.80)	($123.80)	($5.40)	($3.91)	($3.62)	($3.74)	($131.45)
Adjusted Weighted Average Basic Shares Outstanding	25.51M	27.95M	25.05M	1.26M	1.26M	62.79K	1.26M	1.26M	1.26M	1.26M	1.30M
Adjusted Diluted Earnings per Share	($0.28)	($0.30)	($0.32)	($5.60)	($5.80)	($123.80)	($5.40)	($3.91)	($3.62)	($3.74)	($131.45)
Adjusted Weighted Average Diluted Shares Outstanding	25.51M	27.95M	25.05M	1.26M	1.26M	62.79K	1.26M	1.26M	1.26M	1.26M	1.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($123.80)	$0.00	$0.00	$0.00	($3.74)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.00M	25.07M	25.08M	1.26M	1.26M	1.26M	1.26M	1.26M	1.26M	1.34M	1.34M
Normalized Net Operating Profit after Tax (NOPAT)	-5.41	-5.70	-6.11	-5.45	-5.48	-5.79	-5.09	-3.62	-3.40	-3.47	-119
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-241.27	-257.87	-311.86	-324.46	-372.52	-486.76	0.00	-520.70	-808.50	-1,651.33	0.00
NOPAT to Interest Expense	-164.12	-183.85	-218.25	-227.12	-260.77	-340.69	0.00	-364.42	-565.95	-1,156.63	0.00
EBIT Less CapEx to Interest Expense	-241.27	-257.87	-313.18	-329.00	-372.52	-486.76	0.00	-501.30	-808.50	-1,651.33	0.00
NOPAT Less CapEx to Interest Expense	-164.12	-183.85	-219.57	-231.66	-260.77	-340.69	0.00	-345.02	-565.95	-1,156.63	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-26.03%	-30.45%	-32.54%	-8.75%	-0.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Sensei Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sensei Biotherapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sensei Biotherapeutics' net income appears to be on a downward trend, with a most recent value of -$21.09 million in 2025, rising from -$20.10 million in 2020. The previous period was -$30.16 million in 2024. View Sensei Biotherapeutics' forecast to see where analysts expect Sensei Biotherapeutics to go next.

Sensei Biotherapeutics' total operating income in 2025 was -$22.29 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $22.29 million

Over the last 5 years, Sensei Biotherapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Sensei Biotherapeutics' total liabilities were at $4.31 million at the end of 2025, a 38.2% decrease from 2024, and a 22.1% decrease since 2020.

In the past 5 years, Sensei Biotherapeutics' cash and equivalents has ranged from $7.16 million in 2021 to $17.80 million in 2022, and is currently $8.67 million as of their latest financial filing in 2025.

Over the last 5 years, Sensei Biotherapeutics' book value per share changed from -35.01 in 2020 to 14.74 in 2025, a change of -142.1%.

Related Companies

Financial statements for NASDAQ:FTH last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Financials

Financials Breakdown Chart

Sensei Biotherapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Financials

Annual Income Statements for Sensei Biotherapeutics

Quarterly Income Statements for Sensei Biotherapeutics

Annual Cash Flow Statements for Sensei Biotherapeutics

Quarterly Cash Flow Statements for Sensei Biotherapeutics

Annual Balance Sheets for Sensei Biotherapeutics

Quarterly Balance Sheets for Sensei Biotherapeutics

Annual Metrics And Ratios for Sensei Biotherapeutics

Quarterly Metrics And Ratios for Sensei Biotherapeutics

Financials Breakdown Chart

Sensei Biotherapeutics Financials - Frequently Asked Questions

When does Sensei Biotherapeutics' fiscal year end?

How has Sensei Biotherapeutics' net income changed over the last 5 years?

What is Sensei Biotherapeutics' operating income?

How has Sensei Biotherapeutics' revenue changed over the last 5 years?

How much debt does Sensei Biotherapeutics have?

How much cash does Sensei Biotherapeutics have?

How has Sensei Biotherapeutics' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools